Journal of nuclear medicine : official publication, Society of Nuclear Medicine最新文献

{"title":"¹⁷⁷Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?","authors":"Michael Froehner, Klaus Zöphel","doi":"10.2967/jnumed.125.269875","DOIUrl":"10.2967/jnumed.125.269875","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1315"},"PeriodicalIF":9.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2024 SNMMI Highlights Lecture: Neurosciences.","authors":"Richard Carson","doi":"10.2967/jnumed.125.270521","DOIUrl":"10.2967/jnumed.125.270521","url":null,"abstract":"<p><p><i>The Highlights Lecture, presented at the closing session of each SNMMI Annual Meeting, was originated and presented for more than 30 y by Henry N. Wagner, Jr., MD. Beginning in 2010, the duties of summarizing selected significant presentations at the meeting were divided annually among 4 distinguished nuclear and molecular medicine subject matter experts. The 2024 Highlights Lectures were delivered on June 11, 2024, at the SNMMI Annual Meeting in Toronto, Canada. Presented here is the lecture by Richard Carson, PhD, Professor of Radiobiology and Biomedical Imaging and of Biomedical Engineering at Yale School of Medicine (New Haven, CT), who spoke on neuroscience topics presented at the meeting. Note that in the following presentation summary, numerals in brackets represent abstract numbers as published in</i> The Journal of Nuclear Medicine <i>(2024;65[suppl 2]).</i></p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1176-1183"},"PeriodicalIF":9.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translating Discovery into Impact: Owen Witte Talks with Caius Radu and Johannes Czernin About a Life Dedicated to Science and Discovery.","authors":"Owen Witte, Caius Radu, Johannes Czernin","doi":"10.2967/jnumed.125.270520","DOIUrl":"10.2967/jnumed.125.270520","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1157-1159"},"PeriodicalIF":9.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144510150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁷⁶Lu Radiation in Long-Axial-Field-of-View PET Scanners: A Nonissue for Patient Safety.","authors":"Lukas M Carter, Rebecca Milman, Juan Camilo Ocampo Ramos, Adam L Kesner","doi":"10.2967/jnumed.125.269846","DOIUrl":"10.2967/jnumed.125.269846","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1316-1317"},"PeriodicalIF":9.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144083015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative Measurement of Tau Burden in a Dual-Time-Window Dynamic PET Imaging Protocol with [¹⁸F]MK6240.","authors":"Ye Xia, Maeva Dhaynaut, Yanis Chemli, Cristina Lois, Bernard J Hanseeuw, Emma Thibault, Colin Groot, Rik Ossenkoppele, Keith Johnson, Georges El Fakhri, Marc D Normandin, Nicolas J Guehl","doi":"10.2967/jnumed.125.270165","DOIUrl":"10.2967/jnumed.125.270165","url":null,"abstract":"<p><p>This study aimed to test and validate a dual-time-window (DTW) protocol for 6-(fluoro-¹⁸F)-3-(¹H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([¹⁸F]MK6240) dynamic PET imaging in experimental datasets acquired in human subjects. <b>Methods:</b> DTW protocols were tested and validated in datasets previously collected in 25 participants: 13 were cognitively normal, 10 had mild cognitive impairment, and 2 had Alzheimer disease. Participants underwent full 120-min [¹⁸F]MK6240 dynamic PET scans as well as structural MRI. Intermediary 3-dimensional volumes were removed from the acquired dynamic PET images to emulate DTW acquisitions consisting of an early phase and a late phase. Five break durations (30, 40, 50, 60, and 70 min) were investigated to determine the optimal break for 2 study durations (120 and 110 min). Regional brain time-activity curves were extracted using atlases available in the Montreal Neurologic Institute template space and using the FreeSurfer parcellation. Interpolation strategies were tested to recover the missing time points. Distribution volume ratio (DVR) estimates obtained from the DTW time-activity curves were compared with those obtained from the full time-activity curves as reference. Parametric maps were generated for the selected protocol and evaluated. <b>Results:</b> The correlation and agreement between DVR values obtained from the DTW method and the full time-activity curves were overall very good. The DTW protocol with a 60-min break using a biexponential model fit as the interpolation method provided the best compromise between practicality and quantitative accuracy. The mean differences between this DTW and the full acquisition, averaged across brain regions and all subjects, were less than 1% with a corresponding SD of less than 4%, and DVR estimates were not statistically different from those obtained from the full acquisition (<i>P</i> > 0.05). DVR parametric images were visually and quantitatively consistent with those obtained from the full acquisition. <b>Conclusion:</b> This study presents strong support for the use of a DTW protocol with [¹⁸F]MK6240. Such a protocol would be well suited to allow for both quantification of tau and derivation of an index of cerebral perfusion while reducing patient discomfort and increasing scanning efficiency in comparison to a full dynamic acquisition.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1299-1306"},"PeriodicalIF":9.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [¹⁷⁷Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials.","authors":"Raghava Kashyap, James P Buteau, Mathias Bressel, Michal Eifer, Neeraja Bollampally, Price Jackson, Lachlan McIntosh, Shahneen Sandhu, Michael S Hofman","doi":"10.2967/jnumed.125.269640","DOIUrl":"10.2967/jnumed.125.269640","url":null,"abstract":"<p><p>Data are emerging on the prognostic significance of quantitative changes on posttherapy SPECT/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving [¹⁷⁷Lu]Lu-PSMA-617. Our objective was to assess quantitative and visual changes on posttherapy SPECT/CT as prognostic biomarkers for overall survival (OS) among patients in 3 clinical trials: LuPSMA Phase 2 (ANZCTR12615000912583), LuPARP (NCT03874884), and PRINCE (NCT03658447)]. <b>Methods:</b> We segmented the total tumor burden on posttherapy [¹⁷⁷Lu]Lu-PSMA-617 SPECT/CT using an SUV threshold of 3 to measure SUV_max, SUV_mean, metabolic tumor volume (MTV), and total lesion activity (TLA). We assessed the prognostic value of changes in these quantitative parameters and new lesions identified visually on SPECT/CT after cycle 2 for OS using the Cox proportional hazards model, with age, Gleason score, and change in prostate-specific antigen (PSA) as covariates. <b>Results:</b> Eighty-five patients with mCRPC were analyzed (46 from LuPSMA Phase 2, 25 from PRINCE, and 14 from LuPARP). Patients eligible for inclusion had received at least 2 cycles of [¹⁷⁷Lu]Lu-PSMA-617 with a follow-up time of at least 12 mo. Among these patients, 18 (21.2%) had new metastases visible on cycle 2 SPECT/CT, and this was prognostic for OS in univariate (hazard ratio [HR], 2.38; 95% CI, 1.36-4.18; <i>P</i> = 0.002) and multivariate (HR, 2.85; 95% CI, 1.36-5.98; <i>P</i> = 0.01) analyses. Seven (8.2%) patients with PSA reductions had new lesions on posttherapy SPECT/CT. Reductions in TLA (HR, 0.98; 95% CI, 0.97-1.00; <i>P</i> = 0.016) and MTV (HR, 0.98; 95% CI, 0.96-1.00; <i>P</i> = 0.009) (per 10% increase for both) were associated with OS on univariate analysis but not on multivariate analysis. Changes in SUV_max and SUV_mean were not associated with OS. There was moderate correlation among changes in PSA from cycle 1 to cycle 2 and MTV (correlation coefficient = 0.55; 95% CI, 0.39-0.69; <i>P</i> < 0.001) and TLA (correlation coefficient = 0.56; 95% CI, 0.40-0.69; <i>P</i> < 0.001). <b>Conclusion:</b> The presence of new metastases on posttherapy SPECT/CT after cycle 2 is an independent prognostic biomarker for OS in patients with mCRPC and could guide future prospective research to improve treatment strategies for patients with poor prognoses.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1265-1270"},"PeriodicalIF":9.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Prospective Provincial Registry of ¹⁸F-PSMA PET/CT for Recurrent Prostate Cancer: Results for 4,135 Men.","authors":"Andres Kohan, Ur Metser, William Luke, Mohammed Rashid, Deanna L Langer, Pamela MacCrostie, Bo Green, Victor Mak, Girish S Kulkarni, Antonio Finelli, Bobby Shayegan, Stephen E Pautler, Laurence Klotz, Marlon Hagerty, Luke T Lavallée, Catherine Hildebrand, Glenn Bauman","doi":"10.2967/jnumed.125.269653","DOIUrl":"10.2967/jnumed.125.269653","url":null,"abstract":"<p><p>The PSMA-PET Registry for Recurrent Prostate Cancer study was initiated in Ontario, Canada, to provide access to and characterize the performance of ¹⁸F-prostate-specific membrane antigen (PSMA) PET/CT among men with recurrent prostate cancer. <b>Methods:</b> Between October 2018 and September 2022, 4,135 men were enrolled in PREP. Eligibility included suspected prostate cancer recurrence after prior definitive treatment (radical prostatectomy or radiotherapy). Men were enrolled in 1 of 6 predefined clinical cohorts and imaged with ¹⁸F-DCFPyL at 1 of 6 participating sites. Standardized reports delineated sites of recurrence and changes in disease management after PET/CT. Linkage to provincial databases allowed estimation of overall survival (OS) and use of salvage radiotherapy after PET/CT. <b>Results:</b> The median follow-up was 1.8 y. Significant predictors of a positive PET/CT scan on multivariate analysis included a higher prostate-specific antigen level at the time of PET/CT and cohort (highest for cohort 4, whose cancer had progressed during salvage hormone therapy). Significant predictors of management change were type of recurrence (highest for isolated locoregional disease) and higher prostate-specific antigen level. Significant predictors of worse OS included cohort (worst for cohort 4) and extent and type of metastases (worst for mixed bone, lymph, and visceral or extensive metastases). A change in disease management after PET/CT was a significant independent predictor of improved OS rates. <b>Conclusion:</b> PREP facilitated access to ¹⁸F-PSMA PET/CT and demonstrated high rates of disease detection. Significant factors associated with survival were clinical scenario, pattern of metastases, and change in disease management after ¹⁸F-PSMA PET/CT.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1223-1231"},"PeriodicalIF":9.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automated Total-Body Perfusion Imaging with ¹⁵O-Water PET Using Basis Functions and Organ-Specific Model Selection.","authors":"Anna Åhlström, Elin Lindström, Teemu Maaniitty, Hidehiro Iida, Henri Kärpijoki, Jens Sörensen, Juhani Knuuti, Mark Lubberink","doi":"10.2967/jnumed.124.269409","DOIUrl":"10.2967/jnumed.124.269409","url":null,"abstract":"<p><p>Long-axial-field-of-view PET with ¹⁵O-water allows perfusion to be measured in the whole body simultaneously. The purpose of this work was to describe a method for automated computation of total-body parametric perfusion images using PET information only and to validate the perfusion and volume of distribution (<i>V</i> _T) values obtained by comparing them with the gold standard (nonlinear regression analysis). <b>Methods:</b> Data from 10 subjects at Turku PET Centre were evaluated. Each subject underwent a 4-min 40-s dynamic PET/CT scan starting simultaneously with a controlled bolus administration of 350 MBq of ¹⁵O-water. Arterial and venous blood curves were defined using cluster analysis. Delay correction was performed by down-sampling the PET volume, using nonlinear regression for estimation of the delay for each subvolume, interpolation of delay values to the original matrix, and delay correction of all voxel time-activity curves, allowing for linearization of the model. Total-body perfusion images were calculated using several basis function implementations of the single-tissue-compartment model, considering the variations in blood supply to different organs. Model selection for each voxel was performed using cluster analysis to identify different organs. Perfusion and <i>V</i> _T values based on the automated parametric imaging method were validated by comparison of mean organ values with nonlinear regression of the appropriate compartment models to whole-organ time-activity curves. <b>Results:</b> The results showed good agreement between the parameters achieved from the automated parametric images and nonlinear regression. Correlation (<i>R</i> ²) and agreement between linear and nonlinear analyses were high, with an <i>R</i> ² of 0.99 for both perfusion and <i>V</i> _T, with a slope of 0.98 and 1.01 for perfusion and <i>V</i> _T, respectively. <b>Conclusion:</b> Perfusion and <i>V</i> _T values based on automated total-body parametric analysis agreed well with those based on nonlinear regression of whole-organ time-activity curves.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1307-1313"},"PeriodicalIF":9.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144510149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Errata.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":"66 8","pages":"1277"},"PeriodicalIF":9.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144765901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extravasation Frequency of [¹⁷⁷Lu]Lu-DOTATATE: Insights and Implications Derived from 1,314 Cycles of Treated Patients-A Single-Site Analysis.","authors":"Gunjan Kayal, Finn Augensen, Lisa Bodei, Bae Chu, Harry Marquis, Lukas M Carter, John Humm, Adam L Kesner","doi":"10.2967/jnumed.124.269411","DOIUrl":"10.2967/jnumed.124.269411","url":null,"abstract":"<p><p>Extravasation of radiopharmaceuticals raises potential concerns, including adverse tissue reactions and reduction in both quantitative accuracy and therapeutic efficacy. This study presents a single-center experience reviewing extravasation events during [¹⁷⁷Lu]Lu-DOTATATE administration in peptide receptor radionuclide therapy, assessing their frequency, impact on patient care, and dosimetric effects. <b>Methods:</b> [¹⁷⁷Lu]Lu-DOTATATE was administered intravenously to outpatients following standard peptide receptor radionuclide therapy protocols. Whole-body planar imaging was performed 3-4 h after injection to confirm administration and assess extravasation, indicated by focal increased uptake at the infusion site. Qualitative image reviews by nuclear medicine physicians or technologists flagged potential extravasations. For these cases, regions of interest were delineated over the infused and contralateral arm and on the thighs. Extravasated activity was quantified relative to injected and whole-body activity. Absorbed dose calculations were performed using the MIRD formalism, assuming a monoexponential clearance model and accounting for varying extravasate volumes, with infiltration depths ranging from 2 to 7 mm. Statistical analyses compared retained activity and dosimetric parameters between extravasation and control groups. <b>Results:</b> Among 1,314 administrations in 365 outpatients, 14 cases (1.1%) had increased uptake at the infusion site, suggesting extravasation. The maximum radiopharmaceutical retention at the infused site was less than 1% of total injected activity and less than 2.1% whole-body activity (accounting for bladder voiding). The corresponding extravasated activity related to administered activity was 0.07% and 0.01% in the extravasation and control groups, respectively (<i>P</i> < 0.001). The extravasation group had higher absorbed dose estimates at the infusion site than did the control group (median, 0.53 Gy [range, 0.12-1.23 Gy] vs. 0.32 Gy [range, 0.17-0.71 Gy]; <i>P</i> = 0.3), with a significantly higher median extravasated dose (0.14 Gy [range, 0.03-0.67 Gy] vs. 0.02 Gy [range, 0.0-0.19 Gy]; <i>P</i> < 0.001). We did not observe any radiogenic tissue reactions. <b>Conclusion:</b> Extravasation during [¹⁷⁷Lu]Lu-DOTATATE therapy was rare and resulted in minimal dosimetric consequences, with absorbed doses at the infusion site well below the thresholds for deterministic effects and soft-tissue necrosis. These findings indicate that extravasation had a negligible impact on treatment efficacy and patient safety in this patient cohort, reinforcing the safety of [¹⁷⁷Lu]Lu-DOTATATE administration protocols and emphasizing the low clinical risk associated with radiopharmaceutical extravasation during therapy.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1258-1264"},"PeriodicalIF":9.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144510151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}